Cadila Pharmaceuticals Ltd.

The Medicines Patent Pool was on to a good thing when it signed a licensing agreement with Pfizer for nirmatrelvir while it was still an investigational COVID-19 antiviral treatment candidate PF-073

The Medicines Patent Pool (MPP) was on to a good thing when it signed a licensing agreement with Pfizer Inc. for nirmatrelvir while it was still an investigational COVID-19 antiviral treatment candi

In a setback for the Japanese bioventure, AnGes, Inc. has discontinued a government-supported R&D project for an injected DNA plasmid vaccine for the original Wuhan strain of COVID-19. While the Osa

Cadila Pharmaceuticals Ltd. , the privately-owned Indian player, says it has expanded its oncology portfolio by introducing a biosimilar to Avastin (bevacizumab) in its local market. Named Bevaro, the